Executive Summary

After a product dossier has been reviewed by AIFA, the CTR will conduct a analysis to determine whether the product is innovative and the reimbursement class that it should be assigned. This section considers the criteria governing these decisions, the different reimbursement classes, and the considerations governing orphan, generic and biosimilar products.